Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research note

A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel

Elad Goldberg, Haim Ben Zvi, Liron Sheena, Summer Sofer, Ilan Krause, Ella H. Sklan, Amir Shlomai

Introduction

The rapid spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its high burden on health systems have led to a global effort to identify drugs that may reduce morbidity and mortality [1]. Testing previously identified drugs for their efficiency in reducing SARS-CoV-2 replication is a straightforward avenue for timely antiviral therapy implementation.

Remdesivir is a produg converted to an adenosine nucleoside triphosphate analogue. This analogue acts as an irreversible chain terminator, blocking transcription by the viral RNA polymerase [2]. Remdesivir demonstrated SARS-CoV-2 antiviral activity both in vitro and in vivo [3,4]. Clinical trials, however, were inconclusive or showed limited efficiency [5]. The WHO open-label randomized Solidarity trial interim results did not show any significant effect of remdesivir on any tested parameter [6]. However, the Adaptive
COVID-19 Treatment Trial (ACTT-1) showed that remdesivir was superior to placebo in shortening the time to recovery in non-intubated patients [7]. Here we aimed to test the potential of remdesivir to reduce viral replication, as assessed by repeated nasopharyngeal PCR tests, in a real-life setting.

Methods

COVID-19 patients (n = 142, females 40.47%, median age 70 years (IQR 59–80.75)), admitted to the coronavirus ward at Rabin Medical Center between March and November 2020, who had at least three nasopharyngeal SARS-CoV-2 quantitative RT-PCR tests during hospitalization, were included. Of these, 29 patients received remdesivir, based on disease severity and time from onset of symptoms, while the remaining 113 non-treated patients served as controls. For baseline demographics see supplementary tables 1 and 2. Treated patients received intravenous remdesivir (200 mg on day 1, followed by 100 mg on days 2–5 in single daily infusions). The study was approved by the institutional review board (0252-20-RMC) and the Tel-Aviv university ethics committee (0001269-3). Test results and demographic data were collected from the patients’ medical records. Cycle threshold (Ct) values of the nucleocapsid gene were used to assess the viral loads. RT-PCR was performed using the Allplex™ 2019-nCoV Assay (Seegene). To test the effect of remdesivir on nasopharyngeal viral load, we calculated the differences in Ct values (Δ) between patients’ tests. Student’s t-tests for two independent samples were applied to test the difference between treatment groups. Analysis of covariance (ANCOVA) was applied to adjust these comparisons to age, gender and intubation (yes/no). A linear model for repeated measures was performed for testing the statistical significance of the difference in changes across the three tests, adjusted to the parameters mentioned above. Chi-squared tests were applied for testing the statistical significance of the difference in the binary variable increase/decrease between treatment groups. Logistic regressions were applied to adjust these comparisons to the parameters mentioned above. The data were analysed using SAS® v. 9.4 or GraphPad Prism.

Fig. 1. Ct values from control and remdesivir-treated patients. First, middle and last Ct values (A,B,C, respectively) from the nucleocapsid gene from control and remdesivir treated patients were compared (n = 142). The difference (Δ) between the indicated test Ct values is shown (A, B, C, p 0.977, p 0.362, p 0.228, respectively, unpaired Student’s t-test). The Ct values of the first and last test in the control or remdesivir-treated patients are shown both for all patients (D, first p 0.365, last p 0.109, unpaired Student’s t-test) or non-intubated patients only (E, first p 0.203, last p 0.088, unpaired Student’s t-test). ns, non-significant.
Results

The average number of tests was 5.34 ± 2.67 in the control vs. 4 ± 1.7 in the remdesivir group. The differences in Ct values (Δ) between patients’ first and last tests were calculated (Fig. 1A). Overall, a 128-fold reduction in viral load was detected in both the control and the treated patients, with no significant difference between the groups (Ct 7.07 ± 6.85 vs. 7.08 ± 7.27, p 0.977). Since some of those patients were admitted for extended periods (maximal hospitalization length = 55 days), we performed the same analysis on the first and middle tests (Fig. 1B) and the middle and last tests (Fig. 1C). No detectable differences were noted (4.6 ± 6.65 vs. 3.34 ± 6.59, p 0.362 and 2.44 ± 4.9 vs. 3.74 ± 6.16, p 0.228, respectively). Since our study was retrospective, we verified that the average test intervals were similar between the control and remdesivir groups (7.14 ± 6.16 and 7.07 ± 5.52 respectively, p 0.923, student’s t-test). The control and remdesivir groups significantly differed only in the intubation rates (12.4 vs. 41.4% respectively p 0.0003); thus these comparisons were further adjusted to age, gender and intubation status using ANCOVA. The corrected means showed no significant differences from the original analysis (first to last, p 0.768; first to middle, p 0.94; middle to last, p 0.504). In addition, a linear model for repeated measures was performed to test the statistical significance of the difference in changes across the three tests, adjusted to the parameters mentioned above, between treatment groups. To further verify the results, we converted the numerical values of the differences across the tests into dichotomous values (increase/decrease). Chi-squared tests were applied for testing the statistical significance of the difference in the viral load between treatment groups (first to last, decreasing 11.5% vs. 13.8%, p 0.7349; first to middle, 17.7% vs. 31%, p 0.012, middle to last, 29.2% vs. 24.1%, p 0.588). Logistic regressions were applied to adjust these comparisons to age, gender and intubation (first to last, p 0.418; first to middle; p 0.696, middle to last p 0.7831). Of note, remdesivir-treated patients had slightly lower viral loads than non-treated controls on their first test; this difference, however, was not significant (26.8 ± 7.05 vs. 25.67 ± 6.02, p 0.365, Fig. 1D). This difference remained non-significant when the last tests of both groups were compared (33.94 ± 5.22 vs. 32.54 ± 5.78, p 0.109). Since some studies suggested that remdesivir is only efficient for individuals diagnosed early and required oxygen supplementation [8], an additional analysis comparing the Ct values between non-intubated treated and untreated patients was performed. Ct values were similar between these groups at their first test (27.74 ± 4.76 vs. 25.67 ± 7.1, p 0.2034, Fig. 1E). Ct values remained similar when each patient’s last test was compared (34.4 ± 4.78 vs. 32.58 ± 5.76, p 0.0885). Remdesivir was previously reported to reduce time to recovery, defined by time from admission to discharge [7]. Thus, to measure hospitalization length, we tested the time from the first test to discharge (deceased patients were excluded from this analysis). Analysis of the whole cohort indicated that remdesivir reduced hospitalization by 1.4 days (15.3 ± 11.4 vs. 13.9 ± 9.2, p 0.769, Fig. 2A). When only non-intubated patients were analysed, hospitalization was reduced by 3.1 days (14.2 ± 10 vs. 11.1 ± 5.4, p 0.3, Fig. 2B). These differences, however, were not statistically significant.

Discussion

Only patients with severe disease requiring oxygen support were eligible for remdesivir treatment. There were no clear WHO recommendations until November 2020. Currently, WHO does not recommend remdesivir. While nasopharyngeal viral load is not an established marker for therapeutic effect in hospitalized COVID-19 patients, nasopharyngeal swab Ct values were shown to correlate with infectious virus and clinical outcome [9–12]. Our results indicate that remdesivir treatment of COVID-19 patients did not significantly reduce nasopharyngeal viral load. These results are in line with results from a macaque experiment, showing that remdesivir reduced viral load in the lower but not the upper respiratory tract [13]. In contrast, a clinical study by Wang et al. could not detect any effect of remdesivir on viral load, in neither the upper nor lower respiratory tracts [14]. Our study has the advantage of testing remdesivir efficacy in patients in a real-life setting. However, the lack of PCR tests from the lower respiratory tract in our cohort cannot rule out a possible antiviral effect in the lower respiratory tract.

Hospitalization length was reduced by 1 day when the whole patient cohort was analysed. A more considerable but not

Fig. 2. Hospitalization length in remdesivir treated patients and controls. Time in days from the first recorded test to discharge in all control and remdesivir-treated patients (A, p 0.769, unpaired Student’s t-test) or non-intubated patients only (B, p 0.3, unpaired Student’s t-test).
statistically significant reduction of ~3.1 days was observed in the non-intubated group. Despite the relatively small size of our cohort, these real-life results are in agreement with the ACTT-1 trial, showing a modest effect of remdesivir only in non-intubated patients [7]. Our study limitations are its retrospective nature, which did not allow sampling at regular intervals, and its small sample size. Our results call for real-life higher-powered studies to further evaluate a possible clinical benefit of remdesivir.

Transparency declaration

The authors declare that they have no conflicts of interest.

Author contributions

E.G. and E.H.S. conceptualized the study and its methodology. H.B.Z., L.S. and S.S. collected and analysed the data. I.K., A.S., E.G., and E.H.S. wrote the first draft. All authors reviewed and edited the final manuscript.

Acknowledgements

EHS COVID-19 research is supported by the Milner Foundation.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2021.02.029.

References

[1] McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 2020;157:104859.
[2] Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 2020;6:672–83.
[3] Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PL, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents 2020;55:105933.
[4] Pfuisters AJ, George AS, Schafer A, Leist SR, Gralinksi LE, Dinnon 3rd KH, et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep 2020;32:107940.
[5] Malin JJ, Suarez I, Priesner V, Faktenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev 2020;34. e00162-20.
[6] WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. N Engl J Med 2021;384:497–511.
[7] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Members, remdesivir for the treatment of Covid-19 – final report. N Engl J Med 2020;383:1813–26.
[8] Young B, Tan TT, Leo YS. The place for remdesivir in COVID-19 treatment. Lancet Infect Dis 2021;21:20–1.
[9] Magleby R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park J, et al. Impact of severe acute respiratory syndrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clin Infect Dis 2020;ciaa851. https://doi.org/10.1093/cid/ciaa851.
[10] Maltezou HC, Raftopoulos V, Vorou R, Papadima K, Mellou K, Spanakis N, et al. Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. J Infect Dis 2021;223:1132–8. https://doi.org/10.1093/infdis/jiaa804.
[11] Shlomai A, Ben-Zvi H, Glusman Bendersky A, Shafraa N, Goldberg E, Shlan EH. Nasopharyngeal viral load predicts hypoxemia and disease outcome in admitted COVID-19 patients. Crit Care 2020;24:539.
[12] Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill 2020;25:2001483.
[13] Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020;585:273–6.
[14] Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multi-centre trial. Lancet 2020;395:1569–78.